Abstract: Nonviral gene therapy has significant clinical potential, yet its therapeutic utility has been hindered by low transfection efficiency due to a combination of extracellular and intracellular barriers. Recent developments in formulation and delivery methodology have allowed a number of advances toward high efficiency gene delivery to various cell vtypes and organs. In particular, the extracellular and intracellular pharmacokinetics of plasmid DNA trafficking are better understood in a number of cell systems. Using cationic lipid or polymers (often with receptor targeting), more than 10 5 plasmids can be delivered to a single-cell. Endosomolytic agents promote endosome disruption, and include: weak bases, proton-sponge polymers, fusogenic peptides, viral particles, and photosensitizing compounds. Both classical and nonclassical nuclear localization signal (NLS) peptides have also been tested for enhancement of the probability of nuclear import events, a major rate-limiting step in DNA delivery to nondividing cells. For example, the M9 sequence ' from heterogeneous nuclear ribonucleoprotein A I (hnRNP A I) protein, a nonclassical NLS, has been found to increase gene expression level by more than 10 to ISO-fold in a variety of cell types. This review will concentrate on the current understandings of the basic mechanisms of non viral gene delivery and new approaches in the field.
INTRODUCTION
Nonviral gene therapy encompasses a range of strategies: therapeutic transgene expression via plasmid delivery, DNA vaccines, antisense oligos or ribozymes for targeting of mRNA, mRNA delivery or RNA polymerase/cDNA delivery for cytoplasmic transcription, and RNA-DNA chimerics for gene repair. Antisense reagents involve relatively short, rationally designed sequences of RNA, DNA, or peptide nucleic acid (PNA) to hybridize each target mRNA molecule to block expression. Recently, site-specific repair of genetic mutations has been achieved with the use of RNA-DNA conjugates (termed "chimeraplasts") that facilitate single base changes in DNA through the recruitment of cellular repair factors to a basepair mismatch [1 ,2,3J . Nucleic acid therapeutics can be delivered by ex vivo and in vivo. Ex vivo therapy requires removing cells from patients, modifying them in vitro, and introduction of a genetic drug can be achieved by various routes, such as aerosol inhalation to the lungs, arterial catheterization for cardiovascular delivery, topical delivery to follicles, or more commonly by injection (intravenous, intramuscular, subcutaneous, subdermal or intra-tumoral) [4, 5, 6 ]. The expression of therapeutic genes is dependent on both the efficiency of delivery to the cell surface and the efficiency of intracellular trafficking [7] . Intracellular barriers are especially challenging in nondividing cells, such as the vascular endothelium and smooth muscle cells, neurons, and epithelia.
An ideal nonviral vector should deliver a therapeutic gene into its target for sustained expression. The expression level should be high enough for therapeutic and potentially regulated. To some degree, nonviral approaches attempt to recreate these functionalities. To understand what viruses are capable to transfect their host will have great impacts ..on the designs of non viral transfection vectors. The adenovirus, in contrast to nonviral routes, displays high efficency DNA packaging (core proteins) and protection (capsid), receptor targeting (fiber), integrin-dependent internalization (penton base), acid-dependent endosome escape (penton base), cytoskeletal trafficking (hexon), nuclear pore docking (capsid), and nuclear import (terminal protein). Adenovirus (AdV) is widely used because it can transduce both dividing and non-dividing cells. AdV has an icosahedral capsid which is composed of hexons andpentons. Each penton is associated with a rodlike fiber protein to form the penton capsomere. Initial, high affinity binding of AdV to the surface receptors, coxsackie-adenovirus receptor (CAR) of target cells is mediated by the knob domain of the fiber capsid protein [8J. Following receptor binding, the internalization is mediated by the interaction of five Arg-Oly-Asp (ROD) sequences present within the penton base with its secondary targeting cell receptors, the exY~3 and ex Y~5 integrins which are required for efficient virus internalization [9J. The virus is first internalized in clathrin-coated vesicles which mature into early endosomes that acidify due to a proton pump activation. The low pH environment of the endosome causes a conformational change in the penton base allowing the virion to disrupt and escape into the cytoplasm [1 OJ. Following endosome escape, the virus travels along microtubules toward the nucleus. One possible mechanism is that hexon protein associates with the HSP 70 protein after the virus penetrates into the cell and the HSP 70 is associated with microtubules [11, 12] . The virus transport to the nuclear pore can be inhibited by using microtubule depolymerization agent, nocodazole. The capsid is generally found in the cytoplasm although hexon trimer can undergo some nuclear import [12, 13] . At the nuclear pore, the virus undergoes a sequential disassembly through a proteasedependent pathway prior to nuclear import of the AdV DNA. The penton capsomeres are lost within 2-5 min after entering the cells and most other proteins are released within 15 minutes. The final dissociation of capsid is dependent on attachment of capsid at the nuclear pore complexes (NPCs) which can be inhibited by wheat germ agglutinin (WOA). By using cytosol-dependent in vitro assay, Saphire et al [14J revealed that the AdV DNA import could also be blocked by the competitive excess of classical protein nuclear localization sequences (cNLSs), likely through competition with cNLS on the terminal protein (TP) that caps the linear viral genome. The viral DNA transported into the nucleus is Ca 2 + and energy dependent [15] .
EXTRACELLULAR PROCESSES
In vivo gene delivery faces a variety of physical and biochemical barriers such as anatomical size constraints, interactions with biological fluids and extracellular matrix, and binding to a broad variety of non-target cell types. The extracellular barriers are mainly dependent on the target tissue and delivery method. Steric barriers include mucus, glycoaminoglycan barriers in tissue interstitium and glycocalyx barriers at the cell plasmalemma. Steric barriers include interstitial matrix, pericardium, internal elastic lamina, and endothelial barriers as exemplified by the blood brain barrier. Extracellular barriers may also be biochemical and include nucleases, plasma coagulation, complement activation, and plasma proteins that bind charged components of a nonviral formulation. For example, deliver into the airway epithelia for cystic fibrosis gene therapy has many technical difficulties since the apical membrane provides a thick mucus layer that binds and eliminate vectors via mucus clearance mechanisms. Significant glycocalyx barriers can prevent access of p lasmids to cell surface receptors [4] . Most in vivo clinical trial via nasal delivery or aerosol inhalation have observed beneficial effects, but they rarely meet the theoretical requirement to transfect more than 6-10% of surface epithelial cells to relive patients' symptoms [16] .
Steric Barriers
Any gene therapy aimed at central neur~n system disorders must 'bypass the blood-brain barrier (BBB In vivo studies have shown that cationic liposome/plasmid DNA or oligonucleotide complexes are rapidly cleared from circulation with the highest clearance by the "first pass" organs, such as the lungs, spleen and liver. By complexing reporter plasmid with DOTMA (N[1-(2,3-dioleyloxy)propyl [-N,N,N-triethyl-ammonium) :DOPE (dioleoylphosphatidylethanolamine) (2:1, mol:mol), Mahato et al [24] reported that 15 min after tail _vain inj ection of 60-90 ).l g DNA/mouse, the majority of recovered DNA was found in the lung (83%), liver (11.4%), kidney (2.2%) and spleen (1.9%). The DNA was also cleared quickly from blood (0.08%). 
INTRACELLULAR PROCESSES AND SUBCELLULAR TRAFFICKING
There are three major intracellular processes that affect nonviral gene delivery efficiency: endocytosis, endosome escape (endosomolysis) and nuclear targeting, in which the last step is easily achieved in rapidly dividing cells and is often the rate-limiting step in nondividing cells [32, 33, 34] (Fig. 1) . All gene delivery vectors enter cells either by endocytosis or membrane fusion. While the detailed mechanisms of uptake for many nonviral delivery systems are incompletely resolved, the endocytosis pathway is considered the major route of plasmid internalization during lipofection. The subcellular trafficking process has been visualized in a recent in vitro transfection study carried by Godbey and coworkers [35] . They observed that it takes 30 minutes for the polyethylenimine (PEl) complexed DNA to attach to cell surfaces and form aggregates. Endocytosis occured 2 to 3 hr post-transfection, with nuclear import detected within single cells of the population occurring at 3.5 to 4.5 hr after plasmid/PEl delivery to the cells. After entering the nucleus, the earliest transgene expression was observed within 1 hr. In the context of most plasmid trafficking studies in individual cells in a population, the nucleus of individual cells entering and exiting G2/M may have altered plasmid transport properties and cell cycle remains an important variable in these types of studies.
·3.1 Receptor Targeting and Endocytosis: Lipofection
Mammalian endocytosis can involve phagocytosis, clathrin-dependent receptor mediated endocytosis (RME), and clathrinindependent endocytosis [36] . During plasmid endocytosis by the clathrin-dependent RME pathway, the plasmid containing complex binds surface receptors which then cluster to form clathrin coated vesicles (CCV). Plasmid degradation can occur within endosomes [37] . Within minutes in the early endosomes (pH 6.3-6.8), carrier vesicles transfer the plasmid to the late endosomes (pH 5 -5.5) in which the plasmid resides for 10 to 25 min before arriving in the lysosomes. Lysosomes, with very low pH (t 5), accomplish intracellular digestion using a wide variety of hydrolytic enzymes [37] (Fig. 1 During lipofection, the net charge and size of the lipid head group with the hydrophobicity and length of the tail group have impact on the transfection efficiency both in vitro and in vivo. Fig. (1) . Receptor mediated DNA/liposome uptake pathway with the three major intracellular barriers: endocytosis, endosomolysis and nuclear import.
Nonviral Celie Therapy
Feigner et al. [40] showed that hydroxyethyl derivatives of the parent DOTMA, which contains a methyl group in the head group, improved transfection efficiency, but increasing polar hydroxy alkyl chains decreased transfection efficiency in vitro. The transfection efficiency is also decreased when the length of the saturated aliphatic chain increased from 14 to 18 carbon atoms with the transfection efficiency being lower than that achieved with their unsaturated counterparts. In a related in vivo study, Ren et al [44] showed that increasing the carbon numbers of the backbone that connects the cationic head group and the alkylchains in DOTMA could decrease the transgene expression levels up to 50-fold in mice lung, liver, heart and other organs. The in vitro transfection activity of lipid carriers can not be used to predict their in vivo activities. Floch and coworkers
[45] compared a group cationic phosphonolipids' activities in vitro with cystic fibrosis airway epithelial cells (CFTl) and in vivo with tail vain injection of female Swiss mice by using luciferase as marker gene. They found that the lipid with oleyl acyl chains (GLB43) was very active in vivo, but far less active in vitro. However, its analogue with the myristyl acyl chains (GLB73) has reverse effect with high in vitro activity but almost no activity in vivo. The ratio of DNA to lipid is an additional factor that influences the transfection efficiency. Theoretically, the optimal ratio should be the number of positive charges contributed by the lipid needed to exceed the number of negative charges on the DNA, so that the complex has a net positive charge to facilitate interaction with the net negatively charged cell surface [38J. In practice, charge ratios (+/-) considerably higher than 1 often provide the higher level of transgene expression in vitro [55] . Using TEM to study the cationic liposomes/plasmids complexes, Gustafsson et al [56J showed that excess of lipid can lead to the entrapment of plasmid between the lamellas in clusters of aggregated multi lamellar structures. Similarly free or loosely bound plasmids were found in the vicinity of the complexes when· excess plasmid was used. This effect is also generally true in vivo. By using DOTMA:DOPE (2: 1, mol/mol) as carrier, Mahato et al [46] showed that 3: 1 (+/-) charge ratio yield higher transgene expression than that of lower charge ratio both in the lung and liver of mice. However, this charge ratio has to be adjusted according to the targeted organ. By i.v. administrating DOTMA-based transfection complexes in mice, Anwer et al [47J demonstrated that the charge ratio from 5:1 to 0.8:1 (+/-) significantly reduced DNA levels in the lung, but did not change the DNA levels in the tumor. Various natural and synthetic polymers have been used for packaging DNA: poly-L-lysine (PLL), histones, chitosan, polyethyleneimine (PEl), protamine sulfate, polyethylene glycol (PEG), peptide nucleic acid (PNA), disulfidelinked detergents, amine terminated dendrimers, and biodegradable polymers such as polylacticglycolic acid (PLGA). These materials not only bind, but also condense plasmid. Commercial available PLL has a molecular range from 1 to 300 kDa, is convenient to use, however, can be toxic to the cells at nanomolar concentrations in some instances [66] . The benefit of histones likely involves packaging and DNase protection with little indication that the classical nuclear localization sequence facilitates nuclear targeting of plasmid [67] . Protein tetra-amine spermine was developed as a carrier by Gottschalk et al [68] and they found that peptide tyrosinelysine-alanine-Ilysine )8-tryptophan-lysine was very effective for complexing DNA. DNA binding peptides can also be synthesized to couple with specific cell ligands, thereby allowing receptor mediated targeting of the peptide/DNA complexes to specific cell types. One example is the RGD (arginine-glycine-aspartic acid) sequence. The ROD sequence is a common integrin attachment site in ligands such as fibronectin, laminin, and fibrinogen.
The commonly used PEl (at 2, 25, or 800 lcDa) condense plasmid and increase their stability inside ofthe endosomes potentially by interference of acid-dependent DNase [35, 69, 70] . Recently by using a linear-PEl (22 kDa) as carrier for in vivo plasmid delivery, Zou et al [71] were able to transfect 1-5% of mouse lung cells (2 ng luciferase/mg protein), with other organs remaining refractory to transfection (1-10 pg luciferase/mg protein). Alveolar cells, including pneumocytes, were the main targets when~-galactosidase histochemistry was used to monitor marker transgene expression. A polymer system, named PINCTM (protective, interactive, noncondensing system) has also been developed for plasmid delivery [72, 73] . One example is polyvinyl polymers (PVP), which might form hydrogen bound with DNA to reduce their negative charge, protect them from DNase, and facilitate the uptake in tumors [73] Many chemicals, such as cytochalasin B, bafilomycin A and nocodazole have been used to study or alter plasmid processing within the endosome/lysosome pathway. Cytochalasin B blocks phagocytosis and pinocytosis by inhibiting actin polarization, but not the process of RME. When 5 ug/ml of cytochalasin B was preincubated with rat tracheal epithelial cells, plasmid uptake through pinocytosis and phagocytosis were inhibited by 65% and 93% respectively, but not the uptake through RME. Chloroquine is a weak base which can reduce acidification of endosomes and prelysosomes [91] with the potential for enhancement of endosome disruption. Results are conflicting in different studies and likely cell type specific due to sensitivity to chloroquine toxicity. For examples, Erbacher et al [92] reported that 100 uM chloroquine is needed to yield the maximal transfection efficiency in HepG2 cells with glycosylated-PLL /plasmid complex. However, Cho et aI, [93] reported that chloroquine had no effect in HepG2 cells transfection when asialooro so mucoid-PLL (ASOR-PL) was used. Ogris et al [64] reported that chloroquine increased gene expression approximately IO-fold with PEl (800 kDa) in K562 or Neur02A cells. However, Huang and coworkers [88] reported that chloroquine actually decreased gene expression levels in both cytoplasm and nuclear expression. Kollen and coworkers [80] found that chloroquine used with pCMVLuc/ lactosylated poly-L-lysine complex produced 20% transfection efficiency while chloroquine with glycerol produced 90% transfection.
Berg and coworkers developed a new technique named photochemical internalization (PCI) to increase endosome escape [94, 95] . Photosensitizing compounds, such as AIPcS2a (aluminum phthalocyanine with two sulfonate groups on adjacent rings), endocytosized along with proteins or plasmids, become localized in the membranes of endosomes and lysosomes. After exposure to light, these membrane are destroyed, and the endocytosed DNA released into the cytoplasm. Using this method, they delivered type I ribosome-inactivating proteins, horseradish peroxidase, a p21 ras-derived peptide, and a plasmid encoding green fluorescent protein into cytosol in a light-dependent manner. In a human melanoma cell line the light treatment increased the transfection efficiency more than 20-fold, reaching transfection levels of about 50% of the surviving cells.
Membrane fusion and disruption are common biological processes during viral infection. The haem agglutinin (HA) peptide from influenza virus is one of the best characterized pH -dependent fusion protein. The HA is a trimeric glycoprotein embedded in the viral membrane, and responsible for the specific binding to the cell surface sialic acid-coating receptors and for the fusion of two membranes. The HA trimer has three identical monomers and each monomer is composed of two subunits, the HA 1 and HA2 linked together by a disulfide bond. Uptake by the host cell is facilitated by HAl subunit binding to sialic acidcoated receptors. In the low pH environment, conformational changes in the trimer. Expose the hydrophobic residues in the HA2 subunit towards to the targeting membrane and this hydrophobicity is the driving force for the disruption of the endosome. The N-terminal of HA2 subunit with sequence of GLFGAIAGFIENGWEGMIDO-WYO, includes three negatively charged residues, Glu (11, 15) and Asp (19), which prevent the fusion peptide from forming an a-helix at neutral pH. At low pH, HA2 will form an a-helix after the
